Bind Therapeutics, Inc.

Bind Biosciences, Inc.

Pfizer Corporation

Alkermes Controlled Therapeutics, Inc.

Lyndra Therapeutics, Inc.

Massachusetts Institute of Technology

The Brigham and Women's Hospital, Inc.

Alkermes, Inc.

Alkermes Pharma Ireland Limited

Alkermas Controlled Therapeutics, Inc.

Alkermes Controlled Therapeutics, Inc. I

Stephen E Zale

James I Wright

Mir Mukkaram Ali

Greg Troiano

Jeff Hrkach

Young-Ho Song

Christina Van Geen Hoven

Joyce M Hotz

OluFunmi Lily Johnson

M Gary I Riley

J Michael Ramstack

Paul A Burke

Howard Bernstein

Andrew Bellinger

Rosemary Lynn Kanasty

Nupura Bhise

Jung Hoon Yang

Robert Samuel Langer

Omid C Farokhzad

Mark A Tracy

Jianjun Cheng

Susan C Low

David Dewitt

Benjamin A Teply

Avram Brickner

Amy Grayson

Bennett Carter

Henry R Costantino

Kevin McDonnell

Tyler Grant

M Amin Khan

Colin R Gardner

Robert S Langer, Jr

Henry E Auer

Robert S Langer

James R Dasch

Allen Thomas Horhota

David Altreuter

OluFunmi L Johnson

Hye-Jung Lee

Robert Debenedictis

John Klier

Luis Alvarez De Cienfuegos

Susan A Steitz-Abadi

Susan Low

M Gary Riley

Tina Van Geen Uoven

Benjamin A Tepley

The invention provides gastric residence systems with specifically tailored architectures and methods for making such systems. The components of the gastric residence systems can be manufactured by three-dimensional printing or by co-extrusion. The ability to construct precise architectures for the systems provides excellent control over drug release, in vivo stability, and residence time of the systems.

Materials architecture for gastric residence systems

The invention provides gastric residence systems, or components of gastric residence system such as segments or elongate members of gastric residence systems, with release rate-modulating films and methods for making and using such systems. The release rate-modulating films provide good control over release of agents (such as therapeutic, diagnostic, or nutritional agents) present in the gastric residence system. The films also permit higher drug loading in the gastric residence systems and components of gastric residence systems while maintaining good control over release of agents. Some embodiments of the films can provide resistance against burst release of agent upon exposure to alcohol.

Gastric residence systems with release rate-modulating films

The invention provides gastric residence systems for administration of adamantane-class drugs or pharmaceutically acceptable salts thereof, such as memantine or pharmaceutically acceptable salts thereof, and methods for making and using such systems. The systems provide extended release of drug, reducing the frequency with which the drug must be administered to the patient. The gastric residence systems, or components of gastric residence system such as segments or elongate members of gastric residence systems, can have release rate-modulating films, which provide good control over release of adamantane-class drugs or pharmaceutically acceptable salts thereof present in the gastric residence system. Some embodiments of the films can provide resistance against burst release of adamantane-class drugs or pharmaceutically acceptable salts thereof upon exposure to alcohol.

Gastric residence systems for sustained delivery of adamantane-class drugs

Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer&#x2014;EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.

Therapeutic nanoparticles having EGFR ligands and methods of making and using same

The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.

Cancer cell targeting using nanoparticles

The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.

Stable formulations for lyophilizing therapeutic particles

The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.

Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers

The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.

Drug loaded polymeric nanoparticles and methods of making and using same

The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer.

Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same

The present disclosure generally relates to lyophilized pharmaceutical compositions comprising a sugar, a cyclodextrin, and polymeric nanoparticles comprising a copolymer and a therapeutic agent which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.

The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a vinca alkaloid; and about 50 to about 99 weight percent biocompatible polymer.

Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same

The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a &#x3b1;-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours.

Long circulating nanoparticles for sustained release of therapeutic agents

Growing community of inventors

Hopkinton, MA, United States of America

Stephen E Zale